Deborah Ramsdell has officially filed a Form 3, confirming her role as a director at PDS Biotechnology Corp. This filing is significant as it highlights her involvement in the company's governance and strategic direction.
PDS Biotechnology Corp, identified by CIK 0001472091, operates within the pharmaceutical preparations sector. The company is incorporated in Delaware and has its business address in Princeton, NJ. It is listed under the SIC code for Pharmaceutical Preparations [2834]. Recent filings include a Form 4 also submitted on October 20, 2026.
The filing states that Ramsdell is a director at PDS Biotechnology, but does not detail any specific ownership of securities. It notes that she signed the document on October 20, 2026, affirming her position.
This update may affect various stakeholders, including investors and employees, as leadership changes can lead to new strategies and initiatives within the company.
The filing does not say what happens next.
Additional Details from the Filing
The Form 3 filing indicates that Deborah Ramsdell has no securities owned in PDS Biotechnology Corp, which may suggest that her role is primarily focused on governance rather than direct financial investment in the company at this time.
Furthermore, the filing confirms that Ramsdell's address is the same as the company's business address, located at 303A College Road East, Princeton, NJ 08540. This could imply a close operational relationship between her and the corporate headquarters.
The document also specifies that Ramsdell is not an officer of the company nor a ten-percent owner, which further delineates her role strictly as a director.
"The filing does not provide any insights into her plans or strategies for the company moving forward."
It is also noteworthy that PDS Biotechnology Corp was formerly known as Edge Therapeutics, Inc., with the name change occurring on September 11, 2009. This historical context may be relevant for stakeholders interested in the company's evolution.